Friday, October 21, 2022 12:21:21 PM
10:40 am ET October 21, 2022 (Dow Jones) Print
By Chris Wack
Biohaven Ltd. shares were up 17% to $13.98 Friday after the biopharmaceutical company said it priced a public offering of 25 million common shares at $10.50 each.
The stock hit a 52-week high of $15.33 earlier in the session.
The company has granted the underwriters a 30-day option to buy up to an additional 3.75 million shares.
The offering is expected to close on Tuesday, subject to the satisfaction of customary closing conditions.
Biohaven said it intends to use the proceeds received from the offering for general corporate purposes.
New York Yankees and Duke Basketball
Recent BHVN News
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 04/22/2024 08:05:00 PM
- Biohaven Announces Proposed Public Offering of Common Shares • PR Newswire (US) • 04/17/2024 08:05:00 PM
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates • PR Newswire (US) • 04/13/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:16:45 PM
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments • PR Newswire (US) • 02/29/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:54 PM
- Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/02/2024 12:00:00 PM
- Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting • PR Newswire (US) • 12/01/2023 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:15:28 PM
- Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments • PR Newswire (US) • 11/14/2023 09:05:00 PM
- Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® • PR Newswire (US) • 10/16/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:27 PM
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 10/05/2023 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/04/2023 08:05:45 PM
- Biohaven Announces Pricing of $225 Million Public Offering of Common Shares • PR Newswire (US) • 10/03/2023 03:56:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 01:41:44 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2023 09:09:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/02/2023 09:07:23 PM
- BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES • PR Newswire (US) • 10/02/2023 08:36:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 10/02/2023 08:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 10:58:58 AM
- Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy • PR Newswire (US) • 09/14/2023 11:00:00 AM
- Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies • PR Newswire (US) • 09/05/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2023 09:18:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM